Machine Learning-Guided Discovery of Potential Natural KRAS-G12D Inhibitors for Pancreatic Carcinoma

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Ali Alquraini, Mohammed Alahmari, Faisal K Alkholifi, Yahia Alghazwani, Marwa Qadri, Fadhel A. Alomar, Daniyah A. Almarghalani, Mohd Imran
{"title":"Machine Learning-Guided Discovery of Potential Natural KRAS-G12D Inhibitors for Pancreatic Carcinoma","authors":"Ali Alquraini,&nbsp;Mohammed Alahmari,&nbsp;Faisal K Alkholifi,&nbsp;Yahia Alghazwani,&nbsp;Marwa Qadri,&nbsp;Fadhel A. Alomar,&nbsp;Daniyah A. Almarghalani,&nbsp;Mohd Imran","doi":"10.1007/s12247-026-11123-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The mutation KRAS-G12D found in pancreatic cancer is one of the biggest barriers to developing targeted therapy against pancreatic cancer. This research work tries to discover the potential KRAS-G12D inhibitors through natural products guided by machine learning approaches.</p><h3>Methods</h3><p>The screening process involved a library of 3,634 natural compounds sourced from the SelleckChem database, which were then filtered using the established QSAR model. Among these compounds, 176 potential compounds with appropriate predicted activities (pIC50) were chosen for subsequent testing. The 176 compounds were then docked against the switch-II pocket of the KRAS-G12D mutant protein. Compounds exhibiting docking scores equal to or lower than that of the reference inhibitor MRTX1133 (− 8.9 kcal/mol) were selected for subsequent ADMET and molecular dynamics analyses. The potential candidates were analyzed for their ADMET properties and binding interactions in silico. Further validation of the selected compounds was done by performing a molecular dynamics simulation for 300 ns along with a reference compound.</p><h3>Results</h3><p>KR1 and KR2 compounds were observed to have stable binding to the KRAS-G12D protein with RMSD values between 0.18 nm and 0.25 nm. MM-GBSA binding free energy calculations revealed a favorable interaction with energy levels of -13.57 kcal/mol and − 20.48 kcal/mol, respectively. The DFT analysis revealed that KR1 is more chemically stable due to high HOMO-LUMO gap values (4.669 eV) and low electrophilicity values (0.92 eV). However, KR2 was found to have balanced reactivity properties, with a relatively high electronegativity value (3.537 eV) and ionization potential value (4.828 eV).</p><h3>Conclusion</h3><p>Overall, these computations support the potential of KR1 and KR2 as valuable potential lead compounds of KRAS-G12D. Clearly, these results provide a robust basis for subsequent experimentation to validate their biological effects and therapeutic potential.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-026-11123-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The mutation KRAS-G12D found in pancreatic cancer is one of the biggest barriers to developing targeted therapy against pancreatic cancer. This research work tries to discover the potential KRAS-G12D inhibitors through natural products guided by machine learning approaches.

Methods

The screening process involved a library of 3,634 natural compounds sourced from the SelleckChem database, which were then filtered using the established QSAR model. Among these compounds, 176 potential compounds with appropriate predicted activities (pIC50) were chosen for subsequent testing. The 176 compounds were then docked against the switch-II pocket of the KRAS-G12D mutant protein. Compounds exhibiting docking scores equal to or lower than that of the reference inhibitor MRTX1133 (− 8.9 kcal/mol) were selected for subsequent ADMET and molecular dynamics analyses. The potential candidates were analyzed for their ADMET properties and binding interactions in silico. Further validation of the selected compounds was done by performing a molecular dynamics simulation for 300 ns along with a reference compound.

Results

KR1 and KR2 compounds were observed to have stable binding to the KRAS-G12D protein with RMSD values between 0.18 nm and 0.25 nm. MM-GBSA binding free energy calculations revealed a favorable interaction with energy levels of -13.57 kcal/mol and − 20.48 kcal/mol, respectively. The DFT analysis revealed that KR1 is more chemically stable due to high HOMO-LUMO gap values (4.669 eV) and low electrophilicity values (0.92 eV). However, KR2 was found to have balanced reactivity properties, with a relatively high electronegativity value (3.537 eV) and ionization potential value (4.828 eV).

Conclusion

Overall, these computations support the potential of KR1 and KR2 as valuable potential lead compounds of KRAS-G12D. Clearly, these results provide a robust basis for subsequent experimentation to validate their biological effects and therapeutic potential.

机器学习引导下发现胰腺癌潜在天然KRAS-G12D抑制剂
在胰腺癌中发现的KRAS-G12D突变是开发胰腺癌靶向治疗的最大障碍之一。本研究试图在机器学习方法的指导下,通过天然产物发现潜在的KRAS-G12D抑制剂。方法筛选SelleckChem数据库中的3,634个天然化合物,使用建立的QSAR模型进行筛选。在这些化合物中,选择了176个具有适当预测活性(pIC50)的潜在化合物进行后续测试。然后将176个化合物停靠在KRAS-G12D突变蛋白的开关ii口袋上。对接分数等于或低于参考抑制剂MRTX1133(−8.9 kcal/mol)的化合物被选择用于后续的ADMET和分子动力学分析。分析了潜在候选化合物的ADMET性质和在硅上的结合相互作用。通过与参考化合物一起进行300 ns的分子动力学模拟,进一步验证了所选化合物。结果skr1和KR2化合物与KRAS-G12D蛋白结合稳定,RMSD值在0.18 ~ 0.25 nm之间。MM-GBSA结合自由能的计算结果表明,在-13.57 kcal/mol和- 20.48 kcal/mol的能级上存在良好的相互作用。DFT分析表明,KR1具有较高的HOMO-LUMO间隙值(4.669 eV)和较低的亲电性值(0.92 eV),具有较好的化学稳定性。然而,KR2具有平衡的反应性,具有较高的电负性值(3.537 eV)和电离电位值(4.828 eV)。结论KR1和KR2是KRAS-G12D有价值的潜在先导化合物。显然,这些结果为后续实验验证其生物学效应和治疗潜力提供了坚实的基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书